LH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Laboratory of America Holdings's Total Liabilities for the quarter that ended in Mar. 2024 was $8,556 Mil. Laboratory of America Holdings's Total Assets for the quarter that ended in Mar. 2024 was $16,531 Mil. Therefore, Laboratory of America Holdings's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 0.52.
The historical data trend for Laboratory of America Holdings's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratory of America Holdings Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Liabilities-to-Assets | Get a 7-Day Free Trial | 0.58 | 0.53 | 0.50 | 0.50 | 0.53 |
Laboratory of America Holdings Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Liabilities-to-Assets | Get a 7-Day Free Trial | 0.49 | 0.50 | 0.53 | 0.53 | 0.52 |
For the Diagnostics & Research subindustry, Laboratory of America Holdings's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Laboratory of America Holdings's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Laboratory of America Holdings's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Laboratory of America Holdings's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Liabilities-to-Assets (A: Dec. 2023 ) | = | Total Liabilities | / | Total Assets |
= | 8834.6 | / | 16725.1 | |
= | 0.53 |
Laboratory of America Holdings's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 is calculated as
Liabilities-to-Assets (Q: Mar. 2024 ) | = | Total Liabilities | / | Total Assets |
= | 8556.2 | / | 16531 | |
= | 0.52 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratory of America Holdings (NYSE:LH) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Thank you for viewing the detailed overview of Laboratory of America Holdings's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter J Wilkinson | officer: SVP, Chief Accounting Officer | C/O PHARMACEUTICAL PRODUCT DEVELOPMENT, 929 NORTH FRONT STREET, WILMINGTON NC 28401 |
Kerrii B Anderson | director | WENDY'S INTERNATIONAL, INC, 4288 WEST DUBLIN-GRANVILLE RD., DUBLIN OH 43017 |
Van Der Vaart Sandra D | officer: SVP, Global General Counsel | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
Paul Rothman | director | 6 MEADOW ROAD, BALTIMORE MD 21212 |
Paul R Kirchgraber | officer: CEO, Covance Drug Development | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
Mark S Schroeder | officer: EVP, President-Diagnostics Lab | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
Megan D. Bailey | officer: EVP, Chief Strategy Officer | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
Jonathan P. Divincenzo | officer: EVP, Pres, Central Labs & Intl | 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451 |
Anita Z Graham | officer: EVP, CHRO | C/O THE ADT CORPORATION, 1501 YAMATO ROAD, BOCA RATON FL 33431 |
Thomas Pike | officer: Pres & CEO Clinical Business | C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601 |
Kirsten Marie Kliphouse | director | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
Glenn A Eisenberg | officer: Chief Financial Officer, EVP | P O BOX 1017, CHARLOTTE NC 28201-1017 |
Brian J Caveney | officer: SVP, Chief Medical Officer | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
R Sanders Williams | director | DUKE UNIVERSITY SCHOOL OF MEDICINE, TRENT DRIVE, DURHAM NC 27706 |
Amy B. Summy | officer: EVP, Chief Marketing Officer | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
From GuruFocus
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.